Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) just unveiled an update.
Pharmaron Beijing Co., Ltd. has scheduled a board meeting for March 30, 2026 to review and approve the annual results for the financial year ended December 31, 2025. The board will also consider whether to recommend a final dividend, a decision that could affect shareholder returns and signal management’s view of the company’s financial health and cash position.
The announcement also confirms the current composition of Pharmaron’s board, including executive, non-executive, employee representative and independent non-executive directors. This governance disclosure provides investors with clarity on the leadership overseeing the company’s financial reporting, strategic decisions and potential capital allocation, including any dividend proposals.
The most recent analyst rating on (HK:3759) stock is a Hold with a HK$21.50 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based company listed in Hong Kong that operates in the pharmaceutical and life sciences sector. It provides research, development and related services through its subsidiaries, supporting drug discovery and development activities for clients in the healthcare and biopharmaceutical industries.
YTD Price Performance: 0.87%
Average Trading Volume: 6,689,715
Technical Sentiment Signal: Sell
Current Market Cap: HK$52.82B
Learn more about 3759 stock on TipRanks’ Stock Analysis page.